Fundraising FoxNKIO
London, GB · 3 known investors
Find your way into NKIO
Sign up to see every warm intro you have to NKIO
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NKIO team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
Founders & leadership
HB
Hugh BradyCo-founder
MJ
Matthew J. FuchterCo-founder
AB
Andrew BaxendaleAndrew Baxendale brings over 30 years of experience in drug discovery and development across pharma, biotech, and service sectors, with expertise in business development, licensing transactions, and fundraising. He has held leadership and board positions at biotech companies and has experience in therapeutic development across multiple phases.
Investors · 3
Cambridge Angels grouplisted by Cambridge Angels groupCambridge · $195K – $1.9M
How we know: Cambridge Angels group's portfolio page · Not right? Tell us
Future Planet Capitallisted by Future Planet CapitalLondon
How we know: Future Planet Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does NKIO do?
- NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
- Who founded NKIO?
- NKIO was founded by Hugh Brady, Matthew J. Fuchter.
- Who are NKIO's investors?
- NKIO's investors include Cambridge Angels group, Future Planet Capital, UK Innovation & Science Seed Fund.
- Where is NKIO headquartered?
- NKIO is headquartered in London, GB.